Literature DB >> 16221287

Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases.

Yusuf A Rajabally1, Saiju Jacob, Majed Hbahbih.   

Abstract

Current electrophysiologic criteria for chronic inflammatory demyelinating polyneuropathy (CIDP) are highly specific but poorly sensitive. The required extensiveness and best practical way of performing nerve conduction studies to achieve optimal sensitivity remain unknown. We here initially retrospectively analyzed the motor nerve conduction study results of 20 consecutive patients with a clinical diagnosis of CIDP (four performed prior to, and 16 after, treatment initiation) to assess the sensitivity of six published sets of criteria (Nicolas et al., 2002; Thaisetthawatkul et al., 2002; Ad Hoc Subcommittee of the American Academy of Neurology AIDS Taskforce, 1991; Magda et al., 2003; Hughes et al., 2001; Saperstein et al., 2001), as well as four combinations (Nicolas et al., 2002; Ad Hoc Subcommittee of the American Academy of Neurology AIDS Taskforce, 1991; Hughes et al., 2001; Saperstein et al., 2001, each individually combined with Thaisetthawatkul et al., 2002). Sensitivity was highest for the combination of Nicolas et al. (2002) and Thaisetthawatkul et al. (2002) (100%). We then determined the sensitivity of this combined criteria, using five different, hypothetical, nerve conduction study protocols, applied retrospectively to the neurophysiologic data of our 20 patients (exclusive upper limb studies with proximal stimulations; exclusive lower limb studies; full forearm and foreleg studies without proximal stimulations; right-sided studies with proximal stimulations; and left-sided studies with proximal stimulations). The findings showed that exhaustive upper limb or, alternatively, four-limb forearm and foreleg testing would have proved considerably more sensitive than unilateral or lower limb studies to achieve an electrophysiologic diagnosis of CIDP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221287     DOI: 10.1111/j.1085-9489.2005.10306.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  8 in total

1.  Electrophysiological predictors of steroid-responsiveness in chronic inflammatory demyelinating polyneuropathy.

Authors:  Y A Rajabally; M Narasimhan; G Chavada
Journal:  J Neurol       Date:  2008-04-30       Impact factor: 4.849

Review 2.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

3.  Further insight on A-wave in acute and chronic demyelinating neuropathies.

Authors:  Ferdinando Sartucci; Tommaso Bocci; Davide Borghetti; Giovanni Orlandi; Francesco Manfredonia; Luigi Murri; Fabio Giannini; Alessandro Rossi
Journal:  Neurol Sci       Date:  2010-06-18       Impact factor: 3.307

4.  Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Eduardo Adonias De Sousa; Thomas H Brannagan
Journal:  Curr Treat Options Neurol       Date:  2006-03       Impact factor: 3.972

5.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Eliza E Robertson; Peter D Donofrio
Journal:  Curr Treat Options Neurol       Date:  2010-03       Impact factor: 3.972

6.  Electrophysiological evaluation of chronic inflammatory demyelinating polyneuropathy and charcot-marie-tooth type 1: dispersion and correlation analysis.

Authors:  Ji Hyuk Kang; Hye Jeong Kim; Eun Ryeong Lee
Journal:  J Phys Ther Sci       Date:  2013-11-20

Review 7.  The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy.

Authors:  Vera Bril; Christopher M Blanchette; Joshua M Noone; M Chris Runken; Deborah Gelinas; James W Russell
Journal:  J Diabetes Complications       Date:  2016-05-10       Impact factor: 2.852

8.  Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Filip Eftimov; Ilse M Lucke; Luis A Querol; Yusuf A Rajabally; Camiel Verhamme
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.